In this study we elucidated the role of nonactive JNK in regulating p53 stability. The amount of p53-JNK complex was inversely correlated with p53 level. A peptide corresponding to the JNK binding site on p53 efficiently blocked ubiquitination of p53. Similarly, p53 lacking the JNK binding site exhibits a longer half-life than p53 wt . Outcompeting JNK association with p53 increased the level of p53, whereas overexpression of a phosphorylation mutant form of JNK inhibited p53 accumulation. JNK-p53 and Mdm2-p53 complexes were preferentially found in G 0 /G 1 and S/G 2 M phases of the cell cycle, respectively. Altogether, these data indicate that JNK is an Mdm2-independent regulator of p53 stability in nonstressed cells.
The p53 tumor suppressor protein is a potent transcription factor (Kern et al. 1991; Zambetti et al. 1992; Friedlander et al. 1996) that is activated in response to various DNA-damaging agents (Fritsche et al. 1993; Hall et al. 1993; Zhan et al. 1993 ), leading to cell cycle arrest and/or apoptosis (Canman et al. 1995; Polyak et al. 1996) . Disruption of this pathway occurs in a wide range of human cancers and is highly correlated with the tumorigenic phenotype (Harris 1996; Levine 1997) . The key to the magnitude and duration of p53 activities lies in its stability (Maki et al. 1996; Brown and Pagano 1997) . In normally growing cells, p53 half-life is limited to minutes, whereas cellular stress or exposure to DNA-damaging agents prolongs it to hours (Maltzman and Czyzyk 1984) . Proteins known to alter p53 stability include HPV16-E6 (Huibregtse et al. 1991) , WT-1 (Maheswaran et al. 1995) , E1B/E4orf6 (Querido et al. 1997 ), SV40 T-antigen (Reihsaus et al. 1990; Tiemann et al. 1995) , and Mdm2 (Haupt et al. 1997; Kubbutat et al. 1997) . Whereas association of SV40 T antigen, WT1, or E1B/E4orf6 with p53 increases its stability, the binding of E6 or Mdm2 with p53 accelerates its degradation. To date, Mdm2 is the only cellular protein whose direct association with p53 results in its ubiquitination and subsequent degradation (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997; Fuchs et al. 1998a ). The regulation of p53 stability has been associated with post-translational modifications, including phosphorylation on amino-terminal residues (Shieh et al. 1997; Siliciano et al. 1997) .
In previous studies we found that Jun-N (amino)-terminal kinase (JNK) targets the ubiquitination and stability of its associated proteins, c-Jun (Fuchs et al. 1996) , JunB, and ATF2 . JNK targeting for ubiquitination occurs in a phosphorylation-dependent manner as phosphorylated forms of c-Jun and ATF2 were found to be protected against JNK-targeted ubiquitination. Essential for JNK's ability to target the ubiquitination of ATF2, c-Jun, and JunB is its association with each of these proteins (Fuchs et al. 1996 . Recent evidence for JNK association with p53 provided the foundation for our hypothesis that JNK also has a role in the regulation of p53 stability.
Results and Discussion
The association between JNK and p53 in vivo was first demonstrated via coimmunoprecipitations ( Fig. 1a ; Adler et al. 1997) . JNK-p53 complex was preferentially found in nonstressed cells; after UV irradiation its concentration decreased immensely (Fig. 1a) . Whereas >30% of p53 is in complex with JNK 0.5 hr after UV irradiation, <2% of p53 is bound to JNK after 4-8 hr. The extent of JNK association with p53 is inversely correlated with p53 expression levels, suggesting that JNK could affect p53 stability in nonstressed cells.
Previous studies showed that JNK association with p53 requires amino acids 97-155 within the p53 central domain . A 20-amino acid peptide spanning amino acids 97-116 (designated p7) was found capable of altering p53 phosphorylation . To test the effect of p7 on JNK association with p53, increasing concentrations of the p7 peptide, or its control peptide (c7), were added in vitro to purified forms of JNK and p53. As shown in Figure 1b , p7, but not c7, caused a dose-dependent inhibition of JNK association with p53 (Fig. 1b) . Although able to inhibit the formation of the JNK-p53 complex, p7 would not dissociate the preformed JNK-p53 complex (Fig. 1b) . When added to a solid-phase kinase reaction, p7 inhibited p53 phosphorylation by JNK (Fig. 1b, bottom) .
To test the effect of JNK-p53 association on p53 ubiquitination in vivo, we utilized BALB/3T3/12.1 cells (Harvey and Levine 1991) ; these cells express normal levels of Mdm2, which exhibited weak association with p53 wt (not shown). Transfection of p7 or c7 cDNA to BALB/3T3/12.1 revealed that p7 (but not c7) inhibited the association of endogenous p53 with JNK (Fig. 1c) . To determine the relationship between p53-JNK association and p53 ubiquitination, BALB/3T3/12.1 cells were cotransfected with his p53 and HA-tagged ubiquitin. This approach allows one to follow the amount of the polyu-biquitin chains formed on a substrate in vivo (Treier et al. 1994 ). This assay revealed that p7 (but not c7) transfection markedly decreased p53 ubiquitination (Fig. 1d) .
Further support for JNK's role in regulating p53 stability comes from the use of a p53 construct whose JNKbinding domain was deleted (p53 ⌬p7 ). This mutant was not found in the complex with JNK as assayed by coimmunoprecipitation (Fig. 1c) . Lack of JNK association with p53 ⌬p7 in 10.1 p53 null cells coincided with prolonged half-life of p53 ⌬p7 as compared with the p53 wt (Fig. 1e ). The importance of the 100-150 amino acid region for p53 stability was demonstrated previously as its fusion with a long-lived protein, ornithine decarboxylase, reduced stability of the chimeric protein (Li and Coffino 1996) . Because JNK association with its substrate is a prerequisite for targeting ubiquitination of c-Jun, JunB, and ATF2 (Fuchs et al. 1996 , we determined whether outcompeting JNK with another substrate, c-Jun, would affect p53 stability. Transfecting increasing amounts of c-Jun led to a dose-dependent increase in p53 level (Fig.  2a, I ). These changes were not observed in cells treated with the proteasome inhibitor lactacystin, suggesting that c-Jun does affect p53 stability (Fig. 2a, II) . Importantly, transfection of amino-terminal Jun 1-110 (which lacks DNA-binding capacity) or amino-terminal JNK increased p53 level (Fig. 2a, III) and decreased the amount of p53 that could be coimmunoprecipitated with JNK (Fig. 2a, III) . Similar to its effect in mouse fibroblasts, JNK 1-202 expression led to accumulation of endogenous p53 wt in human melanoma and breast cancer cells (Fig.  2b) . Whereas cotransfection of c-Jun inhibited in vivo ubiquitination of p53 ( Fig. 1d) , pulse-chase labeling with [ 35 S]methionine revealed that the p53 half-life in cells that express high levels of c-Jun was extended to >8 hr ( Fig. 2a, IV) . Cotransfection of c-Jun with p53 ⌬p7 did not elevate the expression of this p53 form (Fig. 3a) , which lacks JNK-binding sites, suggesting that overexpression of c-Jun stabilizes p53 through a JNK-dependent mechanism. Together, these data suggest that c-Jun affects p53 stability by squelching JNK.
The effect of Mdm2 on p53 degradation was demonstrated previously via overexpression of Mdm2 (Haupt et al. 1997; Kubbutat et al. 1997) . Unlike Mdm2 expression, JNK is constitutively expressed at high levels, because of which further increase in JNK expression is expected to have a limited effect on the half-life of JNK-associated proteins. To overcome this problem, we have tested the effect of inactive mutant JNK2 construct (T183A, Y185F; Galcheva-Gargova et al. 1994) on elevated levels of p53. The mutant form of JNK2 183, 185 has attenuated the increase in p53 level mediated by p53 overexpression with or without Jun 1-110 in BALB/3T3/12.1 mouse fibroblasts (Fig. 2c) . Moreover, expression of mutant JNK2 183, 185 prevented taxol-induced accumulation of p53 in MCF7 breast cancer cells (Fig. 2d ). These data suggest that phosphorylation-deficient JNK is capable of targeting p53 degradation. The kinase activity of JNK was also found to be dispensable for targeting ubiquitination of c-Jun (Fuchs et al. 1996) . wt or p53 ⌬p7 constructs. Protein extracts prepared 36 hr after transfection and 8 hr after treatment with lactacystin (5 µM) were processed as indicated above. (d) In vivo ubiquitination of p53 in BALB/3T3/12.1 cells. cDNAs of his p53, ubiquitin-HA, and either c7, p7, or c-Jun were cotransfected into BALB/3T3/12.1 cells. p53 ubiquitination was monitored in immunblots performed on nickel resin-purified proteins. The upper part of the membranes (above 55 kD) was probed with antibodies to HA to identify any p53-associated tagged ubiquitin-HA; the lower part was analyzed using antibodies to p53. (e) In vivo stability of p53 ⌬p7 . p53 wt or p53 ⌬p7 constructs were transfected into 10.1 p53 null cells that were metabolically labeled with 0.5 mCi/ml [ 35 S]methionine for 10 min and chased with medium supplemented with 2 mM of unlabeled methionine. Proteins prepared at the indicated time points were immunopurified using PAb 421 antibodies and analyzed on SDSpolyacrylamide gels via autoradiography.
To investigate the relationship between Mdm2 and JNK targeting of p53 degradation, the level of p53 mutants that cannot associate with Mdm2 (p53 22, 23 ; Lin et al. 1994) or JNK (p53 ⌬p7 ; Fig. 1c ) was monitored in cells that had been transfected with either c-Jun (to squelch JNK) or Mdm2. Although cotransfection of Mdm2 did not affect the level of p53 22, 23 ( Fig. 3a ; Kubbutat et al. 1997) , cotransfection of c-Jun increased the level of the p53 22,23 form (Fig. 3a) , indicating that the stability of p53 that no longer responds to Mdm2 can still be affected by JNK. C-Jun had similar effects on the expression level of p53 wt . Cotransfection of Mdm2 with p53 ⌬p7 decreased the level of this p53 mutant, which is not affected by c-Jun overexpression. Both c-Jun and Mdm2 affected the level of cotransfected p53 wt (Fig. 3a) . These observations confirm that Mdm2 and JNK independently regulate p53 stability.
Because Mdm2 was found to associate with p53 and mediate its degradation, we explored the possible interplay between Mdm2 and JNK. We monitored Mdm2-p53 and JNK-p53 complexes at different phases of the cell cycle in Swiss 3T3 cells that were synchronized by serum starvation. Analysis at 0, 8, 20, and 24 hr after growth release (representing G 0 , G 1 , S, and G 2 /M phases of the cell cycle, respectively) revealed that JNK-p53 complexes were preferentially found in G 0 /G 1 , whereas Mdm2-p53 complexes were primarily found in S and G 2 /M phases of the cell cycle (Fig.  3b) .
Further support for the role of JNK in targeting p53 ubiquitination was obtained through the use of a solidphase in vitro ubiquitination assay. In this assay, beads-bound human his p53 was incubated with targeting proteins, followed by extensive washing and subsequent ubiquitination using reticulocyte lysates that were immunodepleted of JNK and Mdm2. In this system, adding exogenously purified JNK as the targeting molecule resulted in increased ubiquitination of p53 as indicated by the smear at the top of the gel (Fig. 4) . JNK's ability to target p53 ubiquitination was inhibited when p7, but not c7, was added at the targeting step of our in vitro ubiquitination assay. P7's ability to block JNK targeting of p53 ubiquitination suggests that its effects in vivo (Fig.  1c,d ) are primarily mediated through interference with JNK interaction with the endogenous p7 domain on p53. Wild-type Mdm2, added as exogenously purified protein, efficiently targeted p53 ubiquitination, whereas mutant Mdm2, which cannot bind p53, failed to mediate this targeting (Fig. 4b) . In contrast to its inhibitory effects on JNK, p7 did not inhibit Mdm2 targeting of p53 ubiquitination. Efficient targeting of p53 ubiquitination was also achieved using protein extracts from Mdm2/p53 null cells (Jones et al. 1996) . However, targeting p53 ubiquitination by Mdm2/p53 null cell proteins could be inhibited by adding p7. Similarly, immunodepleting JNK from Mdm2/p53 null cell extracts significantly reduced p53-targeted ubiquitination. That JNK immunodepletion did not completely abolish p53 ubiquitination suggests that other p53 targeting mol- ecules may exist in these JNK-depleted Mdm2 null extracts. Supplementing JNK-immunodepleted extracts with purified JNK restored targeting p53 for ubiquitination.
To determine the degree of p53 ubiquitination mediated by JNK, we used in vitro-translated [ 35 S]methionine-labeled p53 as the substrate. Quantifying the polyubiquitinated form of p53 revealed that within 30 min, ∼15% of p53 was targeted for ubiquitination by JNK (data not shown). Targeting of p53 ubiquitination can also be mediated by in vitro-translated wild-type or phosphorylation mutant (JNK2 183, 185 ) forms (data not shown), suggesting that JNK does not require its kinase activities to target p53 ubiquitination, as was observed previously with ATF2 and c-Jun (Fuchs et al. 1996 . Similar targeting occurred when baculovirus-produced human or murine p53 was used as the substrate for these reactions (not shown). These data suggest that via its association, JNK directly targets p53 ubiquitination.
In sum, this study demonstrates that in nonstressed normally growing cells, p53 ubiquitination and degradation are also mediated by JNK. In both Mdm2/p53 null cells and BALB/3T3/12.1 cells, JNK appears to be the principal regulator of p53 ubiquitination. Our data also suggest that Mdm2 and JNK represent two independent pathways for targeting p53 stability. The fact that Mdm2-p53 complexes were found at S and G 2 /M phases of the cell cycle, but JNK-p53 complexes were in G 0 /G 1 phases, suggests that through their targeting of p53 stability in nonstressed cells, Mdm2 and JNK may regulate different cellular functions of p53 during normal cell growth. Our data do not preclude the existence of other targeting molecules, as immunodepletion of JNK from Mdm2 null cell lysates did not completely abolish p53 targeting for in vitro ubiquitination.
In line with our previous studies, stress-mediated JNK activation inversely correlates with targeting of its associated proteins, as shown here for p53. JNK activation via MEKK1 results in p53 phosphorylation, inhibition of Mdm2 association, and p53 ubiquitination as reflected by a prolonged p53 half-life (Fuchs et al. 1998b ). Yet because JNK from UV-treated cells can still associate with recombinant p53 in vitro, it is possible that in vivo p53 phosphorylation in response to stress requires multiple stress kinases, which mediate sufficient changes to p53 conformation to result in p53 dissociation from its targeting molecules.
The emerging model supported by our current data suggests that p53 stability is affected by JNK independently of Mdm2 in a cell cycle-dependent manner. In this model, prolonged half-life, which is characteristic of mutant forms of p53, could be attributed to lack of p53 association with one or both targeting molecules. JNK is likely to be among the growing number of adapter molecules that participate in the formation of the E3 ubiquitin/ligase complex. Such adapters were shown to have key roles in substrate recognition and targeting ubiquitination of yeast CDK inhibitor protein Sic1 (Feldman et al. 1997; Skowyra et al. 1997) . A similar mechanism was described for HPV-mediated p53 degradation through the recruiting of E6-AP ubiquitin ligase with the aid of the E6 viral protein (Huibregtse et al. 1991) . As a targeting molecule that mediates the stability of the oncogene, c-Jun, and the tumor suppressor p53, JNK emerges as a key regulator of cell growth in normally growing cells.
Materials and methods

Preparation of JNK and Mdm2
JNK was purified from 600 mg of protein extract prepared from UVirradiated (60 J/m 2 ) BALB/3T3 cells as described (Adler et al. 1995) . A purified form of JNK (54 kD, as revealed by immunoblotting) was used for in vitro ubiquitination assays (∼1 µg/assay). Mdm2 was prepared from Sf9 cells infected with baculovirus-expressing human Mdm2 cDNA in either wild-type or mutant (⌬1-150) forms and purified as described previously (Chen et al. 1996) . The purity of Mdm2 and JNK was confirmed as single bands seen on silver-stained gels.
Immunoprecipitations/immunodepletions JNK was immunodepleted from reticulocyte lysates and protein extracts of Mdm2/p53 null cells by incubating 700 µg of proteins with 1 µg of antibody to JNK (C-17; Santa Cruz) for 16 hr at 4°C. Protein A/G beads were added to this mixture for 2 hr at 4°C, followed by quick centrifugation. Supernatants were used as JNK-depleted proteins. Monoclonal antibodies were used for immunoprecipitation (clone 333, PharMingen) and for immunodepletion of JNK (clone 666) as described ).
Construction of expression vectors
To express peptides in vivo, oligonucleotides bearing the sequence of p7 (VPSQKTYHGSYGFRLGFLHSG) or c7 control peptide (SPPVVPSQSK-STSYGQGYRF) were cloned, respectively, in-frame into pcDNA3 that carries the penetratin sequence (RQIKIWFQNRRMKWKK), followed by the sequence encoding the HA tag (YPYDVPDYASL). Using antibodies to HA enables detection of these fusion peptides (not shown). To generate a p53 expression vector that is histidine-tagged, cDNA of rat p53 was cloned into a pcDNA3 vector by PCR using 5Ј primer that encodes amino-terminal 6xhis, thus generating the his p53 fusion protein. To generate p53 whose p7 sequence has been deleted, the rat cDNA of p53 (pCMV-his p53) was deleted from amino acids 95-114 (corresponding to amino acids 97-116 of human p53, which constitute the p7 domain) using site-directed mutagenesis (Quick Change, Stratagene), resulting in the p53 ⌬p7 construct. Amino-terminal JNK (amino acids 1-202) and amino-terminal c-Jun (amino acids 1-110) constructs were cloned by PCR into pcDNA3. The integrity and expression of all constructs were verified on the basis of sequencing and immunoblots.
In vitro ubiquitination assay and transfection
The in vitro ubiquitination assay was performed as described . Transfection was performed via lipofection (DOTAP) into subconfluent 60-mm plates. In all cases, equal amounts of DNA were transfected (by adjusting the concentrations of respective constructs with empty mammalian expression vector). in vitro was performed using either purified components (JNK; Mdm2) or whole-cell extracts (WCE) from Mdm2/p53 null cells (Jones et al. 1996) . Where indicated, whole cell extracts were immunodepleted with antibodies to JNK or with naive rabbit serum (NRS). Peptides (p7 or c7) were added (40 µM per reaction) in parallel to addition of the respective targeting protein(s), as indicated. In all cases his p53-associated proteins were subjected to extensive washes before proceeding to the ubiquitination step, which utilizes reticulocyte lysates in the presence of Ub-HA . (I) Immunoblot using antibodies to HA. Polyubiquitinated p53 is marked on the left. (II) A Ponceau S stain of the same membrane to verify that equal amounts of p53 were used throughout the reaction.
